Field Guide · Deconstructed
Antabuse — the decades-old alcohol-aversion drug — turned out, in a Johns Hopkins lab, to kill the dormant persister forms of Lyme that standard antibiotics leave behind. It produced the best human remission data of any persister protocol so far. But it carries a real toxicity ceiling and one absolute, total alcohol-avoidance rule. Here are the honest facts: the science, the safety (read it first), how it’s accessed and dosed, and how to make it stop.
I walked this part of the labyrinth myself — knocked on the doors, read the research, and came back with the map. You don’t have to find the way out alone.
Disulfiram is not a casual option, and generally not a pediatric one. Two things make it different from the herbs and gentler agents elsewhere on this map — read both before anything else.
1. A real toxicity ceiling. In the largest real-world series, the higher, more effective doses came with: peripheral neuropathy (~27%), psychiatric effects (~45–50%), and hepatotoxicity (elevated liver enzymes, with rare serious liver injury). These are dose-related — the dose that works best is the dose that hurts most. Liegner retrospective, Antibiotics 2020
2. The absolute alcohol rule. Disulfiram blocks the enzyme that clears alcohol, so any alcohol triggers a severe reaction — flushing, pounding headache, vomiting, racing heart, chest pain; severe cases can cause arrhythmia, collapse, seizures, even death. And alcohol hides everywhere: vinegars and many sauces, mouthwash, hand sanitizer, aftershave/perfume, cooking extracts (vanilla, almond), some cough/cold medicines. This is a hard, total, label-reading avoidance — not a “mostly.” Disulfiram–ethanol reaction from hand sanitizer, 2020 · Vinegar-induced reaction
Disulfiram — brand name Antabuse — is an old, FDA-approved drug for alcohol-use disorder. For seventy years its only job was aversion therapy: it blocks aldehyde dehydrogenase so that drinking alcohol produces an immediate, miserable reaction, and the dread of that reaction keeps people sober. Nobody thought of it as an anti-infective.
That changed when Ying Zhang’s lab at Johns Hopkins screened thousands of compounds looking for something that could kill the dormant “persister” forms of Borrelia — the round-body, biofilm-sheltered survivors that standard antibiotics like doxycycline leave behind, and that are the leading suspect in why some Lyme goes chronic. Disulfiram landed as a hit against stationary-phase Borrelia in vitro, and lab work also explored it against Bartonella persisters. That lab signal is what launched its repurposing for chronic Lyme. Repurposing disulfiram against B. burgdorferi, bioRxiv 2019 · Bay Area Lyme — the disulfiram story
The mental model: most antibiotics are good at killing active bacteria and bad at killing the dormant persisters hiding in biofilm. Disulfiram’s whole appeal is the reverse — it’s a persister-targeting drug, aimed squarely at the hidden forms that survive a normal course of treatment. That’s why it sits in the “refractory Lyme” column, not the “first-line” column.
This is the unusual part: among all the persister-targeting protocols, disulfiram has the strongest human remission data so far — and that data is still limited and uncontrolled. Both halves are true at once.
Dr. Kenneth Liegner’s 2020 retrospective reviewed ~70 patients with chronic, antibiotic-refractory Lyme. Most reported net benefit, and the striking number: 12 of 33 (~36%) who completed one or two courses of high-dose disulfiram reached an “enduring remission” — clinically well for ≥6 months with no further anti-infective treatment. For a population that had already failed antibiotics, durable remission off all treatment is a genuinely meaningful outcome. Liegner, Antibiotics 2020 · Liegner 3-case report, 2019
The honest label: the best human signal of any persister protocol — and still not proven. A durable-remission rate in a refractory group is more than dapsone or the herbs can show, but it comes from uncontrolled data, the one controlled trial was small and stopped early on toxicity, and nothing has been studied in PANS or in children. This is “a real tool for refractory adult Lyme, used with eyes wide open,” not “this works.”
This decision tree is only for a refractory case where disulfiram is genuinely on the table — an older, monitored patient who has already cleared the safety gate below. Start at the top and follow your situation; each step is backed by the evidence on this page. Tap to open.
A young child, anyone who can’t reliably report neuropathy/mood changes, anyone who can’t guarantee total alcohol avoidance (including hidden sources), or anyone with significant liver concern → this is not the tool. Disulfiram’s human track record is in adults, and its ceiling is real.
An older, closely-monitored patient with refractory Lyme, eyes open on toxicity → you may continue ↓
Disulfiram is a refractory-case move — it belongs after appropriate antibiotics and the gentler herbal/persister options, not before. If those haven’t had a fair trial, start there. If they have and the case is still stuck → keep going ↓
This is off-label — you need a Lyme-literate MD willing to prescribe it and to run liver function tests + neuropathy + psychiatric monitoring on a schedule. Confirm a baseline LFT and the full alcohol-avoidance briefing before the first dose. Jump to access.
Lyme protocols start far below the alcohol-aversion dose — sometimes compounded micro-doses — and ramp up slowly, because aggressive increases destabilize patients and drive the toxicity. One variable at a time, anchored to LFTs and how the patient is actually doing. Jump to dosing.
The effects are dose-related and partly reversible — stopping the drug is the move. Tingling/numbness, mood/psychiatric change, or climbing LFTs → hold or stop and call the prescriber, manage the neuropathy/liver, and keep the alcohol rule until your prescriber clears you. Jump to the reverse.
This is one of the heavier calls on the whole map — and you don’t have to weigh it alone. Minta has all of this synthesized. She’ll look at your child, tell you honestly whether disulfiram even belongs on your table (often it won’t), and if it does, help you frame the candidacy, the monitoring, and the start-low plan as questions for a Lyme-literate prescriber. Let Minta do this with you →
Disulfiram itself is a cheap, generic, FDA-approved drug — but using it for Lyme is entirely off-label, so the access story is about finding a prescriber willing to do it well, not about finding the pill.
Read this as “what experienced Lyme prescribers typically use,” not a prescription. There is no FDA-approved Lyme dose and no pediatric dose at all — every number here must be set and monitored by your prescriber. The universal rule holds harder than anywhere on this map: start very low, titrate very slowly, weight-based, one new thing at a time, with a clinician, and only in a patient who can report how they feel.
| Step | What it looks like in practice |
|---|---|
| Start very low | Well below the alcohol-aversion dose. Fragile/inflamed/poor-detox patients have started as low as ~15–25 mg weekly (compounded); a common gentle start is ~62.5–125 mg every few days. |
| Titrate slowly | Increase in small steps over weeks, weight-based, watching tolerance — never jump the dose. Aggressive increases have destabilized patients. |
| Course length | The remission-associated approach used one or two defined courses of higher-dose therapy — not indefinite use. The drug is run, then stopped, not taken forever. |
| Monitor throughout | LFTs on a schedule + neuropathy checks + psychiatric/mood watch. Rising enzymes, tingling, or a mood shift = hold/stop and reassess. |
The dose-vs-toxicity tension is the whole story. The Liegner data shows the higher doses drove both the durable remissions AND the adverse events — you can’t separate them. That’s why this is an adult, closely-supervised drug: someone has to make the dose call in real time, balancing efficacy against neuropathy, liver, and mood, and stop the moment the body says enough. Liegner, Antibiotics 2020
These are starting points, not a prescription. Minta takes the full picture — age, labs, liver, sensitivities, and whether disulfiram is even appropriate — and turns it into specific, monitored questions to bring a Lyme-literate prescriber. Let Minta frame it for you →
This is the part that matters most. You do not begin disulfiram until you can answer one question out loud: “If this goes wrong, exactly how do I make it stop?” The reassuring part: the drug’s toxic effects are dose-related and partly reversible on stopping — the off-switch is to stop the drug. The non-negotiable part is the alcohol rule.
| The problem | How you make it stop |
|---|---|
| Peripheral neuropathy (tingling, numbness) | Stop or reduce the drug. It’s dose-related and usually improves after stopping, though recovery can be slow — catch it early, which is why a patient must be able to report it. Manage symptomatically with the prescriber. |
| Psychiatric effects (mood, agitation, psychosis-spectrum) | Stop the drug and involve the prescriber promptly. Dose-related and generally reversible on discontinuation. |
| Hepatotoxicity (rising liver enzymes) | Hold/stop on a significant LFT rise and recheck. This is exactly why scheduled liver monitoring exists — you catch it on labs before it’s damage. |
| Overwhelming Herx (die-off worse than the body can clear) | Step back from the dose, open drainage/detox (the same Lyme guardrail — methylation, binders, hydration, bowel/liver/lymph), then resume lower and slower if appropriate. |
Disulfiram neuropathy (dose-related, reversible on stopping) · Disulfiram–ethanol reaction, 2020
Credentials, polish, and how conventional an approach sounds tell you little about whether a practitioner will help your child — or harm them. What does: their behavior and their incentives. Watch those.
Repurposing an alcohol-aversion drug to kill Lyme sounds fringe — so the strangeness tells you nothing. What tells you everything is whether the prescriber treats the toxicity ceiling and the alcohol rule with the seriousness they deserve. Judge the conduct and the incentives.
Disulfiram is the rare entry on this map with the best human remission data of any persister protocol — Liegner’s series showed durable, off-treatment remission in roughly a third of completers with refractory Lyme — and a real toxicity ceiling (neuropathy ~27%, psychiatric ~45–50%, hepatotoxicity) plus an absolute, total alcohol-avoidance rule that reaches into sauces, mouthwash, and hand sanitizer. The remission data is uncontrolled, the one controlled pilot stopped early on toxicity, and nothing has been studied in PANS or in children. So it’s a real refractory-case option — for an older, closely-monitored patient, eyes wide open — not a casual or pediatric one. If it’s on the table: a Lyme-literate prescriber, compounded low start, slow titration, LFT + neuro + psych monitoring, total alcohol avoidance, and a stop plan you can name before the first dose — stop the drug if the body objects; the alcohol rule is the part with no reverse. This is parent education, not medical advice — bring it to your team as questions, not instructions.
Plan B does not partner with drug companies or doctors, and we never endorse anyone whose healing isn’t verified by families. We show you the options and how to vet them yourself — and we’re building parent verification: look up a practitioner and see real family reviews before you trust them. Universal bad reviews? Skip.